-BA.1 is known as Omicron, the parent variant.
-BA.2 is sub-variant that shares many but not all mutations with BA.1. >5000 cases so far
-BA.3 probably antigenically similar to BA.1 as it shares mutations at 417, 446, 484 & other key sites. Only 42 cases are reported so far 2/
-Both BA.1 & BA.2 carry almost all spike RBD mutations 1st noted for Omicron & both furin cleaveage adjacent mutations
-BA.1 & BA.2 have NSP6 deletion seen in other VOC
-BA.2 does not carry spike:69/70del deletion & will thus not be detectable by SGTF (S-gene target failure) 3/
-BA.2 less antigenic escape than BA.1 because it lacks G446S.
-Another sublineage is BA.1 + R346K that is more escape because site 346 is major antigenic site. 4/
It was noticed that a number of genomes whilst having many of the defining mutations of Omicron do not have the full set and also have a number of their own unique mutations. 5/
Figure showing diff in mutations: The yellow column gives the mutations unique to the new 'BA.2' lineage, blue column the mutations unique to the original 'BA.1' lineage of Omicron & the green column those shared by both - i.e. inferred to have arisen prior to the split 6/
Here are calculated binding scores by @jbloom_labs
BA.2 calculated to have *less* antigenic escape than main BA.1 lineage. BA.1 + R346K has *more* escape 7/
Here are site-wise plots that explain why BA.2 is less antigenic escape than BA.1 because it lacks G446S.
BA.1 + R346K is more escape because site 346 is major antigenic site. 8/

BA.2 in Indian context:
Apart from Denmark, BA.2 is increasing in #India & South Africa also.
In India, BA.2 has become the dominant Omicron variant towards end of December. Growing from ~5% in mid December to >50% by beginning of January. 9/
In most other countries, BA.1 remains dominant, though BA.2 seems to slowly growing in share everywhere. 10/
An interactive data site by @corneliusroemer where you can type the name of your country to know the exact prevalence of diff sublineages 👇. 11/
The current events have ‘forced’ me to do a quick, random analysis of global Covid Vaccination (may not be perfect). A short thread….👇 1/
1-Covid vaccines are not providing good protection against infection including ‘symptomatic disease’: the primary endpoint of their efficacy trials
2-They failed to provide reasonable durability of immune response, more so ag the last two global VOC. 2/
3-Though high NAb titers are no guarantee for protection against infection, for a highly immune evading variant like Omicron, one needs several folds(>30-40 folds) higher titers than other variants for protection
Fourth vaccine shot 'not good enough' against #Omicron in #Israel!
A study conducted at Sheba Medical Center indicates a fourth shot of the Pfizer Covid vaccine provides insufficient protection against the Omicron variant!
The researchers though find an increase in antibodies, higher than after the 3rd dose. However, many were found infected with Omicron who received the 4th dose.
Let’s see how Israel, a hyper-vaxxed country, and India, a country with modest coverage of 2-doses of Covid vaccines performing 👇
What would be the future scenario w/ #SARS2 variants?
1. Displacement of Delta by Omicron 2. Long-term co-circulation 3. Omicron wave followed by resurgence of Delta & extinction of Omicron
4-Alternate outbreaks of Omicron & Delta
5-An entirely new VOC may displace the two 1/
We know an Omicron infection protects well against reinfection by Delta in previously vaccinated people, but not so well in those that have not been previously vaccinated. In unvaccinated people an Omicron infection only protects well against Omicron reinfection. 2/
This gives advantage Omicron in a highly vaxxed world. But epidemiology of the two VOC in coming weeks should tell us how efficiently Omicron is displacing Delta 3/
Tested #SARSCoV2 positive today. Despite having three doses of Covid vaccine & past infection in Sep'20! And despite possessing anti-spike Abs higher than post-convalescent titer. So, no respect to hybrid immunity too
There are a few takeaways:
1-Prevention of Omicron infection is unattainable with current vaccines.
2-Since majority of infections result in mild illness, our focus shouldn’t be infections & symptomatic disease 1/
3-Furthermore, the amount of NAbs titer needed to neutralise Omicron is several folds (>20-30 folds) higher than previous VOC. This is not attainable with the available vaccines & not even with boosters
4-Antibody titres depend on individual’s genetic makeup and sex 2/
Is Omicron’s arrival means that Covid is soon going to be endemic?
No, the Omicron’s very existence has in fact underlined concerns about what happens with future Covid mutations. 1/
This is because each successive VOC to emerge through the pandemic – including Alpha, Beta, Delta and now Omicron – has not been a descendant of the previous one, as is typical in flu & seasonal CoVs, allowing immunity to develop. 2/
This pattern means we shouldn’t assume the next variant of interest/concern will emerge from current circulating Omicron viruses – like other variants, it may well have already evolved (or be evolving) somewhere, from a much older ancestor lineage. 3/